OncoImmunology
Volume 9, 2020 - Issue 1
Editorial
Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
Oliver Keppa Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France
https://orcid.org/0000-0002-6081-9558
https://orcid.org/0000-0002-6081-9558, Laurence Zitvogelc Gustave Roussy Cancer Center, Inserm U1015, Villejuif, France;d Gustave Roussy Cancer Center, Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France;e Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France;f Chinese Academy of Medical Sciences, Suzhou Institute for Systems Medicine, Suzhou, Chinahttps://orcid.org/0000-0003-1596-0998
https://orcid.org/0000-0003-1596-0998 & Guido Kroemera Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France;f Chinese Academy of Medical Sciences, Suzhou Institute for Systems Medicine, Suzhou, China;g Pôle De Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;;h Karolinska Institutet, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
https://orcid.org/0000-0002-9334-4405
https://orcid.org/0000-0002-9334-4405